(MedPage Today) — CHICAGO — Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in the near future, with results after 1 year reported here from one of its key phase III trials.
Further…
Source link : https://www.medpagetoday.com/meetingcoverage/acr/118248
Author :
Publish date : 2025-10-31 13:00:00
Copyright for syndicated content belongs to the linked Source.
